Clinical trials: Papillomavirus Infections
Cervical Cancer, Vulvar Cancer
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Protocol V503-021 is a long-term follow-up study of the V503-001 base study (NCT00543543) to evaluate the safety, immunogenicity, and long-term effectiveness of V503 vaccine in preventing cervical cancer and related precancers…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT02653118
- Testing
- V503, GARDASIL
- Volunteers
- 4,453 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Condylomata Acuminata, Papillomavirus Infections
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW).
- Conditions
- Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious
- Trial name
- CARE-1 (NCT03981822)
- Testing
- VP-102 and applicator
- Where
- 4 sites in United States
- Volunteers
- 105 people
- Sponsor
- Verrica Pharmaceuticals Inc.
Genital Warts, Perianal Warts
Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage
This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations…
- Trial name
- NCT01082302
- Testing
- Polyphenon E (Veregen) 15% ointment, Green Tea Beverage with defined catechin content
- Where
- Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- MediGene
WHIM Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not…
- Trial name
- NCT03087370
- Testing
- No intervention
- Sponsor
- X4 Pharmaceuticals
Infections, Papillomavirus
Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00196937
- Testing
- Cervarix
- Where
- 6 sites in Germany, Poland
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Wart; External Genital Organs, Condyloma Acuminata
Safety and Efficacy Study to Test Topical AS101 for External Genital Warts
The purpose of this study is to determine whether the improved topical ointment formulation, AS101, is safe and effective in the treatment of external genital warts in females.
- Trial name
- NCT01555112
- Testing
- Topical AS101
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- BioMAS Ltd
Cervical Intraepithelial Neoplasia, Cervical Cancer
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
This study is to evaluate lot-lot consistency of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) .
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT05426148
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Human Papillomavirus Infection Leading to Cervical Cancer
A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.
The purpose of this study was to assess the safety and reactogenicity of GSK Biologicals' Cervarix vaccine in healthy female Filipino subjects from the age of 10 years onwards, as per the Bureau of Food and Drugs Directive of…
- Trial name
- NCT00730847
- Testing
- Cervarix
- Where
- 2 sites in Philippines
- Volunteers
- 743 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Warts, HPV (Human Papillomavirus)
Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)
Warts are benign epidermal tumors caused by human papillomaviruses (HPVs). The active pharmaceutical ingredient DPCP has been used for many years as a compounded formulation in acetone for the treatment of warts, alopecia areata…
- Conditions
- Common Warts, HPV (Human Papillomavirus), Periungual Warts, Plantar Warts
- Trial name
- NCT02640820
- Testing
- Sensitizing DPCP Ointment, Treatment DPCP Ointment
- Where
- 4 sites in United States
- Volunteers
- 83 people
- Sponsor
- RXi Pharmaceuticals, Corp.
Infections, Papillomavirus
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
This Post Marketing Surveillance (PMS) will collect safety data on the use of GSK Biologicals' human papillomavirus (HPV) vaccine in the local target population of females as per the regulations of the Korean Food and Drugs…
- Trial name
- NCT01101542
- Testing
- Cervarix., Data collection
- Where
- 2 sites in South Korea
- Volunteers
- 3,091 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Warts
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
- Trial name
- NCT00115141
- Testing
- Resiquimod
- Volunteers
- 88 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Infections, Papillomavirus
Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
This study will collect safety data of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in healthy females of Chinese origin who are unable to receive all three doses of commercially available HPV vaccine before…
- Trial name
- NCT00811798
- Testing
- Cervarix
- Where
- Hong Kong
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e.
- Trial name
- NCT01290393
- Testing
- Data collection
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Condylomata Acuminata (External)
Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts
The purpose of this study is to assess the pharmacodynamics, safety and efficacy of omiganan in patients with external genital warts.
- Trial name
- NCT02849262
- Testing
- Omiganan (CLS001) topical gel, Vehicle topical gel
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00369824
- Testing
- Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
- Where
- 50 sites in United States
- Volunteers
- 1,330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Genital Warts
Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)
The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.
- Trial name
- NCT00092482
- Testing
- V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077)
This study will collect safety information on the use of GARDASIL™ in the Philippines.
- Trial name
- NCT01355003
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Papillomavirus, Papillomavirus Vaccines
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
This is a multicentre study in which women were planned to receive either the Human Papillomavirus Vaccine (HPV) vaccine or control.
- Trial name
- NCT00294047
- Testing
- Cervarix
- Where
- 75 sites in United States, Australia and 10 more
- Volunteers
- 5,752 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Recurrent Respiratory Papillomatosis, Papillomavirus Infection
Zopa Retreatment and Vector Shedding in Adults With RRP
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP).
- Conditions
- Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
- Trial name
- NCT06538480
- Testing
- Zopapogene imadenovec (Zopa)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Precigen, Inc